With New Rare Blood Clot Warning, J&J COVID-19 Vaccine Rollout Resumes In EU
Countries May Impose Age Restrictions
Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.
You may also be interested in...
A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.
Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.
US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions
Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.